296 related articles for article (PubMed ID: 33975862)
1. Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Kim ST; Smith SA; Mortimer P; Loembé AB; Cho H; Kim KM; Smith C; Willis S; Irurzun-Arana I; Berges A; Hong JY; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kozarewa I; Pierce AJ; Dean E; Lee J
Clin Cancer Res; 2021 Sep; 27(17):4700-4709. PubMed ID: 33975862
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.
Kim R; Kwon M; An M; Kim ST; Smith SA; Loembé AB; Mortimer PGS; Armenia J; Lukashchuk N; Shah N; Dean E; Park WY; Lee J
Ann Oncol; 2022 Feb; 33(2):193-203. PubMed ID: 34710570
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
Kwon M; Kim G; Kim R; Kim KT; Kim ST; Smith S; Mortimer PGS; Hong JY; Loembé AB; Irurzun-Arana I; Koulai L; Kim KM; Kang WK; Dean E; Park WY; Lee J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35790315
[TBL] [Abstract][Full Text] [Related]
4. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Yap TA; Krebs MG; Postel-Vinay S; El-Khouiery A; Soria JC; Lopez J; Berges A; Cheung SYA; Irurzun-Arana I; Goldwin A; Felicetti B; Jones GN; Lau A; Frewer P; Pierce AJ; Clack G; Stephens C; Smith SA; Dean E; Hollingsworth SJ
Clin Cancer Res; 2021 Oct; 27(19):5213-5224. PubMed ID: 34301752
[TBL] [Abstract][Full Text] [Related]
5. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
[TBL] [Abstract][Full Text] [Related]
6. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H; Hafez N; Doroshow D; Sohal D; Keedy V; Do KT; LoRusso P; Jürgensmeier J; Avedissian M; Sklar J; Glover C; Felicetti B; Dean E; Mortimer P; Shapiro GI; Eder JP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34527850
[TBL] [Abstract][Full Text] [Related]
7. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Dillon MT; Guevara J; Mohammed K; Patin EC; Smith SA; Dean E; Jones GN; Willis SE; Petrone M; Silva C; Thway K; Bunce C; Roxanis I; Nenclares P; Wilkins A; McLaughlin M; Jayme-Laiche A; Benafif S; Nintos G; Kwatra V; Grove L; Mansfield D; Proszek P; Martin P; Moore L; Swales KE; Banerji U; Saunders MP; Spicer J; Forster MD; Harrington KJ
J Clin Invest; 2024 Jan; 134(2):. PubMed ID: 37934611
[TBL] [Abstract][Full Text] [Related]
8. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
9. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
10. The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL; Sanseviero E; Karmokar A; Taylor D; Milo M; Michaloglou C; Hughes A; Mai M; King M; Solanki A; Magiera L; Miragaia R; Kar G; Standifer N; Surace M; Gill S; Peter A; Talbot S; Tohumeken S; Fryer H; Mostafa A; Mulgrew K; Lam C; Hoffmann S; Sutton D; Carnevalli L; Calero-Nieto FJ; Jones GN; Pierce AJ; Wilson Z; Campbell D; Nyoni L; Martins CP; Baker T; Serrano de Almeida G; Ramlaoui Z; Bidar A; Phillips B; Boland J; Iyer S; Barrett JC; Loembé AB; Fuchs SY; Duvvuri U; Lou PJ; Nance MA; Gomez Roca CA; Cadogan E; Critichlow SE; Fawell S; Cobbold M; Dean E; Valge-Archer V; Lau A; Gabrilovich DI; Barry ST
Nat Commun; 2024 Feb; 15(1):1700. PubMed ID: 38402224
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Park S; Kim YJ; Min YJ; Mortimer PGS; Kim HJ; Smith SA; Dean E; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
Cancer; 2024 Feb; 130(4):541-552. PubMed ID: 37843249
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice.
Kiesel BF; Guo J; Parise RA; Venkataramanan R; Clump DA; Bakkenist CJ; Beumer JH
Cancer Chemother Pharmacol; 2022 Feb; 89(2):231-242. PubMed ID: 35066692
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
Socinski MA; Mudd PN; Radomski KM; Steagall A; Lawrence P; Bernard S; Letrent SP; Gonzalez P; Brouwer KL
Anticancer Drugs; 1998 Aug; 9(7):611-9. PubMed ID: 9773805
[TBL] [Abstract][Full Text] [Related]
15. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
Moreno L; Casanova M; Chisholm JC; Berlanga P; Chastagner PB; Baruchel S; Amoroso L; Gallego Melcón S; Gerber NU; Bisogno G; Fagioli F; Geoerger B; Glade Bender JL; Aerts I; Bergeron C; Hingorani P; Elias I; Simcock M; Ferrara S; Le Bruchec Y; Slepetis R; Chen N; Vassal G
Eur J Cancer; 2018 Sep; 100():27-34. PubMed ID: 29936064
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Narayanan S; Lam A; Vaishampayan U; Harshman L; Fan A; Pachynski R; Poushnejad S; Haas D; Li S; Srinivas S
Clin Genitourin Cancer; 2016 Oct; 14(5):432-437. PubMed ID: 27068017
[TBL] [Abstract][Full Text] [Related]
17. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
Burris HA; Kurkjian CD; Hart L; Pant S; Murphy PB; Jones SF; Neuwirth R; Patel CG; Zohren F; Infante JR
Cancer Chemother Pharmacol; 2017 Aug; 80(2):261-273. PubMed ID: 28601972
[TBL] [Abstract][Full Text] [Related]
18. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
19. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
[TBL] [Abstract][Full Text] [Related]
20. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
Kouroussis C; Kakolyris S; Mavroudis D; Androulakis N; Kalbakis K; Agelaki S; Sarra E; Souglakos J; Christodoulakis M; Samonis G; Georgoulias V
Am J Clin Oncol; 2001 Aug; 24(4):404-7. PubMed ID: 11474274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
